Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY2A | P04746 | 3/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.44 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.43 |
| ▸ | FGF1 | P05230 | 2/20 | 0.42 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097727 | 0.97 | LGALS3 (0.46) | AMY2ALGALS3LGALS8LGALS4ENGASE | |
| SCHEMBL17121971 | 0.94 | AMY2A (0.52) | AMY2ALGALS3LGALS8LGALS4ENGASE | |
| SCHEMBL13843815 | 0.94 | AMY2A (0.52) | AMY2ALGALS3LGALS8LGALS4ENGASE | |
| SCHEMBL20079487 | 0.94 | AMY2A (0.52) | AMY2ALGALS3LGALS8LGALS4ENGASE | |
| SCHEMBL19721646 | 0.94 | AMY2A (0.52) | AMY2ALGALS3LGALS8LGALS4ENGASE | |
| SCHEMBL13925880 | 0.94 | AMY2A (0.52) | AMY2ALGALS3LGALS8LGALS4ENGASE | |
| SCHEMBL17364578 | 0.94 | AMY2A (0.52) | AMY2ALGALS3LGALS8LGALS4ENGASE | |
| SCHEMBL16744124 | 0.94 | AMY2A (0.52) | AMY2ALGALS3LGALS8LGALS4ENGASE | |
| SCHEMBL22055340 | 0.94 | AMY2A (0.52) | AMY2ALGALS3LGALS8LGALS4ENGASE | |
| SCHEMBL14768928 | 0.91 | LGALS8 (0.49) | AMY2ALGALS3LGALS8LGALS4ENGASE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153613-B2 | Barrier film-forming germicidal composition for controlling mastitis | DELAVAL HOLDING AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20070275070-A1 | Barrier film-forming germicidal composition for controlling mastitis | DELAVAL HOLDING AB (SE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275070-A1 | Barrier film-forming germicidal composition for controlling mastitis | CUTA, LCT, MGAM | AMY2A 648/4885LGALS3 68/4885LGALS8 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.